Ozempic Injection: CDSCO Approves Breakthrough Diabetes Treatment for Indian Market

CDSCO approves Danish firm Novo Nordisk’s injection for type-2 diabetes patients

New Delhi, Sep 30 (PTI) India’s drug regulator Central Drugs Standard Control Organisation (CDSCO) has approved Ozempic (semaglutide injection) manufactured by Danish pharma company Novo Nordisk for use in adults with type-2 diabetes. According to sources, Ozempic, the once-a-week injection, will be available only on a doctor’s prescription. “Semaglutide Injection (Ozempic@) is indicated for the […]

CDSCO approves Danish firm Novo Nordisk's injection for type-2 diabetes patients

CDSCO approves Danish firm Novo Nordisk's injection for type-2 diabetes patients

CDSCO Approves Danish Drugmaker Novo Nordisk's Injection for Type 2 Diabetes Patients

Get latest articles and stories on India at LatestLY. In a statement provided to ANI, Novo Nordisk has stated that Ozempic is intended for individuals with Type 2 diabetes and will be available only upon a doctor's prescription. India News | CDSCO Approves Danish Drugmaker Novo Nordisk's Injection for Type 2 Diabetes Patients.

Ozempic Injection: CDSCO Approves Breakthrough Diabetes Treatment for Indian Market

The Central Drugs Standard Control Organisation has approved Novo Nordisk's Ozempic, a groundbreaking once-a-week injection for Type 2 diabetes patients in India. Available via prescription, the semaglutide injection not only aids in diabetes management but also reduces cardiovascular and kidney disease risks, setting new standards in diabetes care.

Ozempic set for India launch as weight-loss demand fuels diabetes drug boom

Ozempic is coming to India. Why should this matter to you? Because this world-famous, much-discussed diabetes treatment has also become a global weight-loss phenomenon. And now it could soon be available on your local pharmacy shelves. The once-a-week injection by Danish firm Novo Nordisk is headed for Indian shelves after being cleared by the Central Drugs Standard Control Organisation (CDSCO) — India’s drug regulator — for use in patients with…

Novo Nordisk to launch Ozempic in India, sets stage for GLP-1 market expansion - Express Pharma

Novo Nordisk is set to launch its blockbuster drug Ozempic (semaglutide) in India. This signals a major shift in the country’s diabetes and obesity care market. The once-a-week injectable, already a global best-seller, will complement the company’s existing oral semaglutide for diabetes and recently approved WeGovy for obesity, giving Novo Nordisk a full suite of semaglutide therapies in India. India represents one of the largest patient pools i…